Patient-Oriented Research: The Time is Now

Patient involvement in making medical decisions has been demonstrated to be an important contributor to treatment adherence, patient satisfaction, and health status. Thus, a large amount of literature exists which describes methods for improving health care provider-patient communication and shared decision-making. However, while clinicians rely on evidence-based randomized trials and clinical practice guidelines to inform their recommendations to patients, very little information is available on patients’ preferences for how best to involve them in the development and execution of the studies we collectively work on.

The Canadian VIGOUR Centre (CVC) has been exploring how best to engage patients in clinical research, including as part of our developing national initiative - the Canadian Cardiovascular Research Collaboratory (CCVRC). I recently met with Dr. Catharine Whiteside, Executive Director of Diabetes Action Canada, the Strategy for Patient-Oriented Research (SPOR) Network in Diabetes and Related Complications. Dr. Whiteside kindly shared the SPOR patient engagement framework they have developed, which advocates for “putting patients first”. One of the key approaches identified by the SPOR group is patient involvement across the entire spectrum of research initiatives, including: engagement in the identification of important unanswered questions; collaboration in study development (including methodology); shared trial leadership and decision-making; and, communication related to study progress and results.

Similar patient engagement initiatives are underway in the United States. For example, the Patient Focused Medicines Development (PFMD) group notes that “simply enrolling and following patients as passive research subjects in a clinical trial does not rise to the level of patient engagement. Instead, patients should be treated as valued and valuable partners whose input, advice, and guidance is sought and implemented throughout these processes.” Indeed, PFMD makes a key distinction between patients and partners: “A patient is a person who needs, awaits, and receives medical treatment and care. In contrast, a partner is a person who wants, co-designs, and co-delivers medical treatment and care. In order to commit to more meaningful partner engagement in medicines development, we must invest more time to listen, involve them in finding solutions through co-creation, and engage in constant communication with them throughout the development lifecycle.”

What are we at the CVC doing in light of this highly anticipated change? In collaboration with our academic research organization (ARO) partner, the Duke Clinical Research Institute (DCRI), the CVC is coordinating the Canadian component of a randomized clinical trial where patient engagement is a key priority. The Apo A-I Event Reducing in Ischemic Syndrome (AEGIS-II) trial is a large, international, multicenter Phase 3 trial infusing intravenous apolipoprotein (Apo) A-I (CSL112) to reduce cardiovascular events in acute coronary syndrome (ACS) patients. In AEGIS-II, the CVC and DCRI are committed to ensuring a high-quality, efficient, patient-centered trial by: (1) developing a trial that is feasible and minimally burdensome for participants; (2) increasing enrolment rates by proactively addressing barriers to recruitment and improving study communications and materials; and, (3) driving higher rates of retention and protocol adherence through enhanced value and improved participant experience. Recognizing that patients are our partners in research, not our subjects, we are aiming to engage participants in the conduct, oversight, and dissemination activities of the trial. For example, there is a Canadian representative (enrolled in the phase 2 AEGIS-I trial) on the AEGIS-II Participant Advisory Group, who will help provide input on: the informed consent process, recruitment and retention strategies, tactics, and materials; anticipated participant experience (having themselves had a recent ACS and/or been part of AEGIS-I); and the conduct of the study related to optimizing participant comfort and convenience in the context of the protocol requirements. While this is simply a first step towards more optimal patient-oriented research, we hope that listening, co-creating, communicating, and collaborating with our partners will lead to better engagement and more impactful clinical trial results.

Shaun Goodman
CVC Co-director
We are excited to see with all personnel and departments involved from first enrollment their first patients. Conducting a study in a fast-paced emergency setting has its challenges. Congratulations to the Edmonton team for all their efforts 2018 with a Canadian contribution of 4 patients. Well done SODIUM-HF team!

550 patients were enrolled by the end of July 2018. The project team wishes to thank all Investigators, Coordinators, and Dietitians for their hard work throughout the summer months. Now that enrollment is more than halfway done, plans are underway for the first DSMB meeting.

CVC will disseminate information regarding how sites can prepare for this first interim analyses over the coming months.

NEW SITE ACTIVATION
Welcome Dr. Alexander Zhai, Sarah (Study Coordinator) and Rochelle (Dietitian) from Royal University Hospital in Saskatoon, SK! We look forward to seeing your first patient randomized in the study.

REMINDERS!
Publication Dietary Materials Feedback
Trial Dietitian, Dr. Eloisa Colín, will be requesting further feedback on the publication of dietary materials. Don’t miss out on your chance to provide your feedback and comments on this important publication! If you have any questions, please contact Eloisa at eloisa_colin@yahoo.com.mx.

Data and Invoices
Please remember to log into REDCap and check your site’s queries by clicking on the “Resolve Issues” link in the left hand column. The next quarterly data cut for site payments is September 30, 2018. As a reminder, a visit needs to be fully completed (saved as green / complete in REDCap, all queries resolved, and the Food Record [as applicable] submitted to the Core Lab sodocom@ualberta.ca) in order for payment to be triggered for that visit.

Project Lead Transition
We would like to welcome Melissa Spaling back to the SODIUM-HF trial as the CVC Project Lead starting August, 2018. Many of you have worked with her previously on SODIUM and other CVC trials. Thank you to Nubia Zepeda for her leadership and diligence in managing the trial for the past few years. The project team wishes her the best in her future endeavours!

If you are interested in receiving more information about the SODIUM-HF trial, please contact the Clinical Trial Project Lead, Melissa Spaling, via email at mspsaling@ualberta.ca or 1-800-707-9098, ext 1. You may also contact the SODIUM-HF trial Regulatory Specialist, Kate Dawson, via email at kedawson@ualberta.ca.

If you did not receive a copy of the guide, please contact us so we can send one to you.

VICTORIA-HF Registry
Site start-up is drawing to a close and we wish to extend our gratitude to all of our sites for a successful and timely start! Canada is doing a terrific job with enrollment and we thank you for your efficient and accurate work.

We wish to recognize the following sites for their excellent enrollment efforts:

- Dr. Allen Schaffer and Wendy Janz/Charissa Cepdoza (Winnipeg, MB)
- Dr. Brian Clarke and Kim Ronak/Sneha Patel (Calgary, AB)
- Dr. Mustafa Toma and Carol Marchand (Vancouver, BC)
- Dr. Eva Lonn and Alison Magi/Linda Frenette (Hamilton, ON)

If you are interested in further information about the VICTORIA Heart Failure Registry, please contact the Clinical Trial Project Lead, Karin Kushniruk, at 1-800-707-9098, ext 7 or via email at Kushniru@ualberta.ca or the Regulatory Specialist, Kate Dawson via email at kedawson@ualberta.ca.

HEART-FID
The HEART-FID study is underway with 22 active Canadian sites and almost 50 randomized patients. The majority of sites have now screened at least one patient and over half have randomized! Canada started off the summer on a high note with June seeing the most patients enrolled per month so far. We are excited to see a continued increase in enrollment into the fall.

Important Trial Reminders:
Unblinded Lab Review
Please ensure your designated unblinded study team member reviews the unblinded labs well in advance of an upcoming 6 Month dosing visit. If the unblinded labs are unavailable in Almac, please inform CVC so that we may follow up to obtain these lab results in time for the scheduled visit. Your site process for unblinded lab review should be outlined in your site’s blinding process memo. You can also find more information about who is able to review these unblinded labs in the Post Dosing Unblinding Labs Assessment flow chart.

Site Reference Guide
The new Site Reference Guide was sent to sites on June 26.

This handy guide is your quick go-to document to refer to whenever you have questions about the trial. The Site Reference Guide provides helpful information about contacts, study procedures, data entry, systems, and much more! If you have any questions, please contact Courtney Gubbels at 1-800-707-9098 ext 2 or via email at courtney.gubbels@ualberta.ca or Senior Regulatory Specialist Kalli Belschek, ext 6 or via email at kalli@ualberta.ca.

A special thanks to the team for their diligence in working with all personnel and departments involved from first patient contact to study follow up. We are excited to see enrollment continue to increase over the upcoming months.

The study has reached 27 patients globally as of August 20, 2018 with a Canadian contribution of 4 patients. Congratulations to the Edmonton team for all their efforts enrolling their first patients. Conducting a study in a fast-paced emergency setting has its challenges.

A special thanks to the team for their diligence in working with all personnel and departments involved from first patient contact to study follow up. We are excited to see enrollment continue to increase over the upcoming months.

If you are interested in further information regarding this trial, please contact Clinical Trial Project Lead Courtney Gubbels at 1-800-707-9098 ext 2 or via email at courtney.gubbels@ualberta.ca or Senior Regulatory Specialist Kalli Belschek, ext 6 or via email at kalli@ualberta.ca.

Sponsored by the Canadian Institutes of Health Research (CIHR) and University Hospital Foundation, SODIUM-HF is a multicentre, randomized, open-label, blinded endpoint Intervention trial. Funding: CIHR in Heart Failure.

ClinicalTrials.gov Identifier: NCT02812179

Site start-up is drawing to a close and we wish to extend our gratitude to all of our sites for a successful and timely start! Canada is doing a terrific job with enrollment and we thank you for your efficient and accurate work.

We wish to recognize the following sites for their excellent enrollment efforts:

- Dr. Allen Schaffer and Wendy Janz/Charissa Cepdoza (Winnipeg, MB)
- Dr. Brian Clarke and Kim Ronak/Sneha Patel (Calgary, AB)
- Dr. Mustafa Toma and Carol Marchand (Vancouver, BC)
- Dr. Eva Lonn and Alison Magi/Linda Frenette (Hamilton, ON)

If you are interested in further information about the VICTORIA Heart Failure Registry, please contact the Clinical Trial Project Lead, Karin Kushniruk, at 1-800-707-9098, ext 7 or via email at Kushniru@ualberta.ca or the Regulatory Specialist, Kate Dawson via email at kedawson@ualberta.ca.

HEART-FID
The HEART-FID study is underway with 22 active Canadian sites and almost 50 randomized patients. The majority of sites have now screened at least one patient and over half have randomized! Canada started off the summer on a high note with June seeing the most patients enrolled per month so far. We are excited to see a continued increase in enrollment into the fall.

Important Trial Reminders:
Unblinded Lab Review
Please ensure your designated unblinded study team member reviews the unblinded labs well in advance of an upcoming 6 Month dosing visit. If the unblinded labs are unavailable in Almac, please inform CVC so that we may follow up to obtain these lab results in time for the scheduled visit. Your site process for unblinded lab review should be outlined in your site’s blinding process memo. You can also find more information about who is able to review these unblinded labs in the Post Dosing Unblinding Labs Assessment flow chart.

Site Reference Guide
The new Site Reference Guide was sent to sites on June 26.

This handy guide is your quick go-to document to refer to whenever you have questions about the trial. The Site Reference Guide provides helpful information about contacts, study procedures, data entry, systems, and much more! If you have any questions, please contact Courtney Gubbels at 1-800-707-9098 ext 2 or via email at courtney.gubbels@ualberta.ca or Senior Regulatory Specialist Kalli Belschek, ext 6 or via email at kalli@ualberta.ca.

A special thanks to the team for their diligence in working with all personnel and departments involved from first patient contact to study follow up. We are excited to see enrollment continue to increase over the upcoming months.

The study has reached 27 patients globally as of August 20, 2018 with a Canadian contribution of 4 patients. Congratulations to the Edmonton team for all their efforts enrolling their first patients. Conducting a study in a fast-paced emergency setting has its challenges.

A special thanks to the team for their diligence in working with all personnel and departments involved from first patient contact to study follow up. We are excited to see enrollment continue to increase over the upcoming months.

If you are interested in further information regarding this trial, please contact Clinical Trial Project Lead Courtney Gubbels at 1-800-707-9098 ext 2 or via email at courtney.gubbels@ualberta.ca or Senior Regulatory Specialist Kalli Belschek, ext 6 or via email at kalli@ualberta.ca.

Sponsored by the Canadian Institutes of Health Research (CIHR) and University Hospital Foundation, SODIUM-HF is a multicentre, randomized, open-label, blinded endpoint Intervention trial. Funding: CIHR in Heart Failure.

ClinicalTrials.gov Identifier: NCT02812179

Site start-up is drawing to a close and we wish to extend our gratitude to all of our sites for a successful and timely start! Canada is doing a terrific job with enrollment and we thank you for your efficient and accurate work.

We wish to recognize the following sites for their excellent enrollment efforts:

- Dr. Allen Schaffer and Wendy Janz/Charissa Cepdoza (Winnipeg, MB)
- Dr. Brian Clarke and Kim Ronak/Sneha Patel (Calgary, AB)
- Dr. Mustafa Toma and Carol Marchand (Vancouver, BC)
- Dr. Eva Lonn and Alison Magi/Linda Frenette (Hamilton, ON)

If you are interested in further information about the VICTORIA Heart Failure Registry, please contact the Clinical Trial Project Lead, Karin Kushniruk, at 1-800-707-9098, ext 7 or via email at Kushniru@ualberta.ca or the Regulatory Specialist, Kate Dawson via email at kedawson@ualberta.ca.
As a reminder all study visits including EOT, EOS and Post Treatment phone call should be entered in Marvin within 48 hours of the visit so that Data Management can review and clean the data in an efficient manner.

We want to thank you for your efforts to keep patients engaged in the study and appreciate your continued diligent follow up of them during this end of study phase.

**General Reminders**

- Please continue to report all events, even if they are just “suspected” events.
- Ensure copies of all study communications are on file at your site (per the listing that CVC sends out) and let CVC know if you are missing any.
- Send invoices to CVC for any outstanding items per your site’s contract/budget.
- Promptly notify CVC of any temperature excursions for Rivaroxaban.

If you have any questions about this trial, please contact the Clinical Trial Project Lead, Jodi Parrotta at 1-800-707-9098, ext. 3 or via email at jodi.parrotta@ualberta.ca or Regulatory Specialist Paula Priest at paula.priest@ualberta.ca.

**QUALITY - ICH GCP E6**

In case you are not already aware, ICH GCP E6 was updated from R1 to R2 in November 2016. The reason for this update was to address the changes in the complexity of clinical trials and technology since 1996, when the guidelines were first released. To quote the ICH E6 (R2) Amendment per ICH’s “E6(R2) Step 4 Presentation” found on http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html#e6-2.

ICH E6(R1) has been amended to encourage implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting while continuing to ensure human subject protections and reliability of trial results.

New terms such as “Certified copy,” “Monitoring Plan” and “Validation of computerized systems” have now been added to the guidelines. Additional recommendations pertain to PI responsibilities (Delegation of Duties and Maintenance of Records); Sponsor responsibilities (Quality Management and Risk-based Monitoring); and Essential Documents. Health Canada formally adopted ICH GCP E6(R2) on April 1, 2018, with the aim of implementing these new guidelines by April 1, 2019. As for training, there is a new 10-module ICH E6 R2 updated training, there is a new 10-module ICH E6 R2 update training module available through the Collaborative Institutional Training Initiative (CITI), to which many of our sites belong through their institution. The course includes the International Council for Harmonisation (ICH)-E5 (R2) guidelines, Health Canada- Division 5, and The Tri-Council Policy Statement 2.

We strongly encourage all sites to update their GCP training and send CVC a copy of updated training records for your study team.

The summer months have brought some exciting milestones to fruition in Canada! The first three Canadian sites were activated:

- Dr. Sohrab Lutchmedial & Gail O’Blenis – New Brunswick Heart Centre (Saint John, NB)
- Dr. Christopher Fordyce & Shirley Lim – Vancouver General Hospital (Vancouver, BC)
- Dr. Olga Toleva & Kiran Atwal/Dolores Friesen – St. Boniface General Hospital (Winnipeg, MB)

A heartfelt congratulations to Dr. Fordyce and his team for enrolling the first Canadian patient on July 31!

We continue to work closely with our sites on ethics submissions and contract/budget negotiations and are on track to have the majority of our current sites activated for enrollment by October. We appreciate all the work that goes into study start up and thank all of our participating sites for pushing through this over the next few weeks to help us meet this timeline.

The second Investigator Meeting took place in Chicago this July and was very well received. Thank you to our Canadian sites for taking the time to attend these very important meetings.

While many of the sites have now been selected in Canada we are still welcoming additional sites to participate. As a reminder, AEGIS-II is a large, international, multi-centre Phase 3 trial of infusing an intravenous formulation of apolipoprotein A-I (CSL112) to reduce cardiovascular events in acute coronary syndrome patients. CSL112, an intravenous formulation of apo-A-I, enhances cholesterol efflux capacity, and therefore has the potential to reduce plaque burden, stabilize plaque lesions at risk of rupture and decrease the rate of early recurrent events.

If you treat this patient population and may be interested in participating or hearing more, please contact Clinical Trial Project Lead, Lyndsey Garrity at 1-800-707-9098, ext 8 or via email at lyndsey.garrity@ualberta.ca or Senior Regulatory Specialist Kalli Bielecki at 1-800-707-9098, ext 9 or via email at kalli@ualberta.ca.

Sponsored by CSL Behring LLC, this is a Phase 3, Multicentre, Double-Mbl, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.

ClinicalTrials.gov Identifier: NCT01473223

**AEGIS-II**

The FEAST-HF trial will explore the potential beneficial effects of dietary fiber supplementation, compared with placebo, in patients with Heart Failure. Fermentable dietary fibers are emerging as therapeutic agents for improving health but also have systemic effects and thus the potential to improve symptoms of other diseases.

This trial has the potential to open up avenues leading to new treatments for patients with heart failure.

Currently this trial is in its pilot phase at the University of Alberta and we anticipate Dr. Ekelowitza and his team will enroll their first patient soon.
CVC 2017 Annual Report

We are pleased to share with you our recently published 2017 Annual Report. As we celebrate our 20th anniversary at CVC, we reflect on our organization’s development, evolution and direction. For this year’s report we sought inspiration from Janus, the ancient Roman god of beginnings and transitions. Janus is often represented as a god with two faces – one which looks backwards and the other forwards. His spirit exactly captures what permeates our organization’s lasting values and future orientation.

The timeless vision and mission, contained within our compass, is constantly energized by the organization’s lasting values and future orientation.

Beyond 2000 - B2K18

Beyond 2000 is a symposium held every year in conjunction with the Canadian Cardiovascular Congress.

This year B2K18 will be held at the Metro Toronto Convention Centre South Building (Exhibition Hall G) in Toronto, Ontario on October 22, 2018.


Please refer to the attached insert for more details.

Further information about B2K18 will be available soon on the CVC website: http://thecvc.ca/conferences-and-events/.

CVC News

Linn Moore recently joined the CVC as a Research Associate working with Dr. Padma Kaul. Linn received her BSc from the University of Gothenburg, Sweden, and recently completed her PhD in clinical cardiopulmonary physiology at the University of Alberta. Throughout her PhD training, Linn has been teaching courses in anatomy and exercise physiology, has supervised numerous undergraduate research students, and has been involved with the activities of the office of the Respiratory Health Clinical Strategic Network within Alberta Health Services. Linn can be contacted at 780-492-1651 or by email at linn.moore@ualberta.ca.

Leah Luoma recently joined the CVC as an Academic Research Administrator. She received her BSc in Molecular Genetics and a PhD in Medical Genetics, both from the University of Alberta. Her PhD focused on the gene regulatory processes involved in human neurodevelopment and cognition. After her PhD, Leah held a Postdoctoral Fellowship in the Department of Surgery before joining the CVC in May 2018. Over the course of her training, her interests have turned from understanding genetic mechanisms and neurobiology to translation and synthesis of biomedical and health research information to realize health outcomes. Leah can be reached at 780-492-7732 or by email at lehua@ualberta.ca.

Sunjida Islam recently joined the CVC as a biostatistician. She received her MBBS (Bachelor in Medicine and Bachelor in Surgery) from Bangladesh, and MSc in Epidemiology from the University of Alberta. Following her MSc, Sunjida worked in the Pediatrics department for two years in hospital in low- but not high-altitude natives.

Melissa Spaling has recently returned from maternity leave. She has resumed her position as Clinical Trials Project Lead at CVC and is working on the SODIUM-HF Trial and other projects. Melissa has worked at CVC since 2013 and is happy to return to the team! Melissa can be reached at 1-800-767-9098, ext 1 or mspaling@ualberta.ca.

Publications


Michalak M, Armstrong PW. Exploiting New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Directions? Circ Heart Fail. 2018;11:3064-3063. doi: 10.1161-

Publications


CVC gratefully acknowledges our sponsors and the funding support provided by:

Bayer Health Care AG
Bayer Health Care Pharmaceuticals Inc.
Canadian Institute of Health Research
CSL Behring LLC
Heart & Stroke Foundation
Leuven Research and Development
Luitpold Pharmaceuticals Inc.
Merck & Co., Inc.
University Hospital Foundation

Chronicle Editorial Board

Paul W. Armstrong  Lyndsey Garrity  Jodi Parrotta
Kalii Belseck  Shaun Goodman  Melissa Spaling
Kate Dawson  Courtney Gubbels  Tracy Temple
Justin Ezekowitz  Karin Kushniruk  Kris Reay

This newsletter is published periodically as a service to Canadian investigational sites. The purpose is to provide information of interest to individuals involved in cardiovascular clinical trials managed by the Canadian VIGOUR Centre, University of Alberta in Edmonton, Alberta, Canada.

Address for Inquiries:
2-132 Li Ka Shing Centre for Health Research Innovation, University of Alberta
Edmonton, AB, Canada, T6G 2E1
Phone: 1-800-707-9098 Fax: 780-492-0613
www.thecvc.ca
@CVC_UAlberta